Each month, subscribers to The Formulary® receive print and electronic versions of at least six monographs reviewing new drug entities or related drugs within a category. Some reviews take a second look at currently available drugs, whereas other preliminarily evaluate agents about to be released–just in time for use with your Pharmacy and Therapeutics Committee or for counter detailing. The monographs are prepared by clinical and drug-information pharmacists and are reviewed by expert pharmacists and physicians. Through the cooperation of The Formulary, Hospital Pharmacy has arranged to publish selected reviews in this column. If you would like more information about The Formulary or its related electronic bulletin board, known as the F.I.X.® (Formulary Information Exchange, write to: The Formulary, 33971 Selva Road, Suite 250, Dana Point CA 92629; or call 1-800-322-4349.
Get full access to this article
View all access options for this article.
References
1.
Zemplar package literature.Abbott Laboratories; April 1998.
2.
BilstadJ.FDA Approval Letter for Zemplar (NDA 20-819). April 17, 1998. (http://www.fda/gov)
3.
Anonymous.Abbott receives FDA approval for Zemplar for suppression of parathyroid hormone in chronic renal failure patients. Abbott Laboratories; April 23, 1998. (http://www.abbott.com/news/).
4.
Daisley-KyddR.E., MasonN.A.Cal-citriol in the management of secondary hyperparathyroidism of renal failure. Pharmacotherapy.1996; 16: 619–30.
5.
SlatopolskyE.A new analog of calcitrol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hyper-calcemia. Am J Kidney Dis.1995; 26: 852–60.
6.
TakahashiF.A new analog of 1,25-(OH)2D3, 19-nor-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis.1997; 30: 105–12.
7.
SlatopolskyE.Biological activity of 19-nor(19-nor-1,25-(OH)2D2): A new vitamin D drug for renal osteodys-trophy [abstract]. International Congress of Nephrology. Sydney, Australia; June 1997.
8.
FinchJ.L.Differential effects of 1,25-(OH)2D3, 19-nor-1,25 -(OH)2D2 on calcium and phosphate resorption in bone [abstract]. The American Society of Nephrology Annual Meeting. San Antonio, TX; November 1997.
9.
SlatopolskyE.Pharmacokinet-ics of paracalcin (19-nor-1a,25-dihydroxyvitamin D2) in healthy subjects [abstract]. International Congress of Nephrology. Sydney, Australia. June 1997.
10.
LeeR.D.Disposition and excretion of [3H]19-nor-1a,25-dihydoxyvitamin D2 in humans [abstract]. American Society for Bone and Mineral Research 19th Annual Meeting. Cincinnati, OH; September 1997.
11.
LiachF.19-Nor-1a,25-dihy-droxyvitamin D2 (paracalcin): An effective vitamin D analog suppresses PTH secretion in hemodialysis (HD) patients [abstract]. The American Society of Nephrology Annual Meeting. New Orleans, LA; November 1996.
12.
BadalamentiJ.Safety and efficacy of paracalcin (19-nor-1a,25-dihydroxyvitamin D2) in hemodialysis patients: Results of a double-blind, placebo-controlled, multicenter trial [abstract]. International Congress of Nephrology. Sydney, Australia; June 1997.
13.
MartinK.J.A single center double-blind placebo controlled randomized trial of 19-nor-1a,25-dihydroxyvitamin D2 (“19-nor”) in patients on hemodialy-sis [abstract]. American Society for Bone and Mineral Research 19th Annual Meeting. Cincinnati, OH; September 1997.
14.
LindbergJ.19-nor safely and effectively reduces iPTH levels in hemodialysis patients [abstract]. The American Society of Nephrology Annual Meeting. San Antonio, TX; November 1997.
15.
SlatopolskyE., CavanaughJ.Safety of paracalcin (19-nor-1a,25-dihydroxyvitamin D2) in healthy subjects [abstract]. International Congress of Nephrology. Sydney, Australia; June 1997.
16.
Rebetron Combination Therapy package literature.Schering-Plough Corporation; May 1998.
17.
Anonymous.Supplemental NDA submitted for use of Rebetron Combination Therapy in treatment-naïve hepatitis C patients. PRNewswire. June 16, 1998. (http://www.prnewswire.com)
18.
Anonymous.National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology.1997; 26(suppl 1): 2S–10S.
19.
CadaDJ, (ed), LevienT.L., BakerD.E.Drug Evaluation—Interferon Alfacon-1.The Formulary Monograph Service.Dana Point, CA; December 1997.
20.
BellobuonoA.Ribavirin and interferon-a combination therapy vs. interferon-a alone in the retreatment of chronic hepatitis C: A randomized clinical trial. J Viral Hepat.1997; 4: 185–91.
21.
ReichardO.Therapy of hepatitis C: Alpha interferon and ribavirin. Hepatology.1997; 26(suppl 1): 108S–11S.
22.
Di BesceglieA.M.Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med.1995; 123: 897–903.
23.
BodenheimerH.C.JrTolerance and efficacy of oral ribavirin treatment for chronic hepatitis C: A multicenter trial. Hepatology.1997; 26: 473–7.
24.
Di BesceglieA.M.A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology.1992; 16: 649–54.
25.
DusheikoG.Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J Hepatol.1996; 25: 591–8.
26.
KoskinasJ.Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients. J Med Virol.1995; 45: 29–34.
27.
LaiM-YLong-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology.1996; 111: 1307–12.
28.
BrillantiS.Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol.1995; 23(suppl 2): 13–6.
29.
BrillantiS.A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology.1994; 107: 812–7.
30.
ChemelloL.The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol.1995; 23(suppl 2): 8–12.
31.
LindsayK.L.Therapy of hepatitis C: Overview. Hepatology.1997; 26(suppl 1): 71S–77S.
32.
MoussalliJ.Management of hepatitis C. J Viral Hepat.1998; 5: 73–82.
33.
SchvarczR.Combination treatment with interferon alfa-2b and rib-avirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol.1995; 23(suppl 2): 17–21.
34.
SchalmS.W.Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci.1996; 41(12 suppl): 131S–134S.
35.
SchvarczR.Combined treatment with interferon alpha-2b and rib-avirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol.1995; 46: 43–7.
36.
ReichardO.Randomised, double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet.1998; 351: 83–87.
37.
GaneE.J.A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology.1998; 27: 1403–7.
38.
BizollonT.Pilot study of the combination of interferon alfa and rib-avirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology.1997; 26: 500–4.
39.
AljumahA.A.Long-term rib-avirin therapy for recurrent hepatitis C after liver transplantation. Transplant Proc.1997; 29: 514.
40.
MazzaferroV.Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant Proc.1997; 29: 519–21.
41.
McHutchisonJ.G.Ribavirin and interferon for recurrent posttransplantation HCV infection: To treat or no to treat?[editorial]. Hepatology.1997; 26: 505–6.
ScottoG.Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol.1996; 28: 505–11.
